Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Aldagen |
---|---|
Information provided by: | Aldagen |
ClinicalTrials.gov Identifier: | NCT00654433 |
Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease. A portion of cord blood cells (ALD-101) will be separated from the cord blood unit and given approximately 4 hours after the standard cord blood transfusion.
The study will test if the supplemental cells will increase the speed at which normal levels of circulating blood cells are re-established after transplant.
Condition | Intervention | Phase |
---|---|---|
Inherited Metabolic Diseases Lysosomal Storage Disorders Peroxisomal Storage Diseases Hematopoietic Stem Cell Transplantation |
Biological: ALD-101 |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase III Trial of ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transplantation (UCBT) in Patients With Inborn Errors of Metabolism |
Estimated Enrollment: | 40 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
I: Experimental |
Biological: ALD-101
A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
|
Subjects will be hospitalized and undergo high doses of chemotherapy which will destroy the child's normal cells including their bone marrow (which forms blood cells) in order to prepare their body for the umbilical cord blood transplant. The cord blood transplant is intended to rescue your child's bone marrow from the bad effects of the procedure. The child will receive 80% of a standard cord blood transplant followed by 20% supplemental stem cell called ALD-101.
The study will evaluate if these cells (ALD-101) will repopulate the bone marrow more rapidly after transplant. This would shorten the period of time that the transplanted subject would be at risk for infection and bleeding and would also decrease the number of red blood cell and platelet transfusions needed.
ALD-101 has been used as a supplement to cord blood transplant in twenty-eight children with genetic diseases and malignancy in one previous clinical study that is on-going.
The main purpose of this research study is to test whether a portion of cord blood cells that have been separated from a cord blood unit (ALD-101) will increase the speed at which normal levels of circulating blood cells are re-established after transplant. This is the experimental part of this study. ALD-101 is also being tested to see if it is safe.
Ages Eligible for Study: | up to 16 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
confirmed diagnosis of inherited metabolic diseases; including the following:
Exclusion Criteria:
Contact: Rachael Crozier, MS, RN | 919-484-2571 ext 260 | rcrozier@aldagen.com |
Contact: Becky Durham | 919-484-2571 ext 242 | bdurham@aldagen.com |
United States, California | |
Mattel Children's Hospital at UCLA | Recruiting |
Los Angeles, California, United States, 90095 | |
Contact: Kristen C. Venick, RN, MSN, CPN 310-825-6708 kvenick@mednet.ucla.edu | |
Contact: Alison Bell, RN, NP 310-825-6708 abell@mednet.ucla.edu | |
Principal Investigator: Theodore Moore, MD | |
United States, New York | |
Mt. Sinai Medical Center | Recruiting |
New York, New York, United States, 27705 | |
Contact: Rosa Chu 212-241-7022 rosa.chu@mssm.edu | |
Contact: Nita Narayan 212-241-4142 nita.narayan@mssm.edu | |
Principal Investigator: Gustavo Del Toro, MD | |
United States, North Carolina | |
Duke University | Recruiting |
Durham, North Carolina, United States, 27705 | |
Contact: Jennifer Baker, RN 919-668-6536 baker133@mc.duke.edu | |
Contact: Caroline Elkins, RN 919-668-1280 caroline.elkins@duke.edu | |
Principal Investigator: Joanne Kurtzberg, MD |
Study Director: | Laurence Keller, MD | Aldagen |
Principal Investigator: | Joanne Kurtzberg, MD | Duke University |
Responsible Party: | Aldagen, Inc. ( Laurence Keller, MD Chief Medical Officer ) |
Study ID Numbers: | UCBT-002, BB-IND#13502 |
Study First Received: | April 3, 2008 |
Last Updated: | December 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00654433 |
Health Authority: | United States: Food and Drug Administration |
Hurler Syndrome MPS I Hurler-Scheie Syndrome Hunter Syndrome MPS II Sanfilippo Syndrome MPS III Maroteau-Lamy Syndrome MPS VI Krabbe Disease Globoid Leukodystrophy Metachromatic Leukodystrophy MLD Adrenoleukodystrophy |
ALD AMN Sandhoff Disease Tay Sachs Disease Pelizaeus Merzbacher PMD Neiman-Pick Disease Alpha-mannosidosis Inherited metabolic diseases Inborn errors of metabolism Lysosomal storage diseases Peroxisomal storage diseases Hematopoietic stem cell transplantation Umbilical cord blood transplantation |
Hunter-McAlpine syndrome Mucopolysaccharidosis II Pick Disease of the Brain Gangliosidosis (GM2) Type1 Addison's disease Leukodystrophy, Metachromatic Frontotemporal dementia Tay-Sachs disease Aphasia, Primary Progressive Leukodystrophy Krabbe leukodystrophy Alpha-L-iduronidase deficiency Metabolism, Inborn Errors Adrenoleukodystrophy Addison Disease |
Primary progressive aphasia Metachromatic leukodystrophy Tay-Sachs Disease Sandhoff disease Leukodystrophy, Globoid Cell X-linked adrenoleukodystrophy Alpha-Mannosidosis Metabolic Diseases Lysosomal Storage Diseases Mannosidase Deficiency Diseases Mucopolysaccharidosis I Genetic Diseases, Inborn Hunter syndrome Lobar atrophy of brain Metabolic disorder |